Oxford Biomedica (LON:OXB – Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%.
Oxford Biomedica Stock Performance
Shares of LON OXB traded down GBX 10 during midday trading on Wednesday, hitting GBX 483. 650,515 shares of the stock traded hands, compared to its average volume of 1,106,726. The firm has a market capitalization of £584.66 million, a P/E ratio of -17.94 and a beta of 1.09. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. Oxford Biomedica has a one year low of GBX 420 and a one year high of GBX 952. The firm has a 50-day moving average of GBX 515.68 and a two-hundred day moving average of GBX 577.12.
Trending Headlines about Oxford Biomedica
Here are the key news stories impacting Oxford Biomedica this week:
- Positive Sentiment: Oxford Biomedica reported 9% first-half revenue growth to £80.2 million and highlighted record commercial activity, including 17 new clients. The company said demand and expansion momentum remain strong. Oxford Biomedica delivers solid H1 growth, record commercial wins
- Positive Sentiment: Management maintained its fiscal 2026 sales outlook despite the first-half results, providing some reassurance that recent client wins are expected to support future growth. Oxford Biomedica H1 Revenue Reaches £80.2 Million as FY2026 Guidance Maintained
- Positive Sentiment: The company is advancing a global quality transformation using Veeva Quality Cloud, an initiative intended to improve quality-management processes as Oxford Biomedica expands its operations and customer base. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
- Neutral Sentiment: Analyst coverage pointed to potential valuation upside, with one earnings preview citing a GF Value estimate approximately 35% above the prevailing valuation. This is an external valuation view rather than company guidance. Earnings To Watch: Oxford BioMedica PLC Q2 2026
- Negative Sentiment: Profitability remains the main concern. Oxford Biomedica reported quarterly EPS of negative 30.39 pence, while its first-half loss widened despite revenue growth. The company also reported a negative net margin and negative return on equity, reinforcing investor concerns about the cost and timing of its expansion. Oxford Biomedica reiterates sales outlook but half-year loss widens
Analyst Upgrades and Downgrades
View Our Latest Report on Oxford Biomedica
Oxford Biomedica Company Profile
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Read More
- Five stocks we like better than Oxford Biomedica
- Gold Defied the Fed’s Rate Hike—These 3 Plays Stand Out
- Thor Industries Is Boring—And That May Be Its Biggest Advantage
- Full Throttle: Kratos and GE Fire Up a Next-Gen Defense Engine
- Sandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
